Identifying Small Molecule-miRNA Associations Based on Credible Negative Sample Selection and Random Walk

Abstract

Recently, many studies have demonstrated that microRNAs (miRNAs) are new small molecule drug targets. Identifying small molecule-miRNA associations (SMiRs) plays an important role in finding new clues for various human disease therapy. Wet experiments can discover credible SMiR associations; however, this is a costly and time-consuming process. Computational models have therefore been developed to uncover possible SMiR associations. In this study, we designed a new SMiR association prediction model, RWNS. RWNS integrates various biological information, credible negative sample selections, and random walk on a triple-layer heterogeneous network into a unified framework. It includes three procedures: similarity computation, negative sample selection, and SMiR association prediction based on random walk on the constructed small molecule-disease-miRNA association network. To evaluate the performance of RWNS, we used leave-one-out cross-validation (LOOCV) and 5-fold cross validation to compare RWNS with two state-of-the-art SMiR association methods, namely, TLHNSMMA and SMiR-NBI. Experimental results showed that RWNS obtained an AUC value of 0.9829 under LOOCV and 0.9916 under 5-fold cross validation on the SM2miR1 dataset, and it obtained an AUC value of 0.8938 under LOOCV and 0.9899 under 5fold cross validation on the SM2miR2 dataset. More importantly, RWNS successfully captured 9, 17, and 37 SMiR associations validated by experiments among the predicted top 10, 20, and 50 SMiR candidates with the highest scores, respectively. We inferred that enoxacin and decitabine are associated with mir-21 and mir-155, respectively. Therefore, RWNS can be a powerful tool for SMiR association prediction.

Development and Validation of a Nomogram for the Prediction of Hospital Mortality of Patients With Encephalopathy Caused by Microbial Infection: A Retrospective Cohort Study

“…In terms of clinical application, the net benefit of patients using nomogram is better than that of SAPS II ( Figure 6 ), and the nomogram shows good performance in predicting hospital mortality of SAE patients. For the evaluation of nomograms, in addition to the above-mentioned AUC value and other methods, some new methods may be needed to evaluate in the future ( Zhou et al, 2019 ; Liu F. et al, 2020 ).…”

A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them

“…A novel nano-compounds encapsulating wild-type p53 (SGT-53) could enhance the inhibitory effects of TMZ on TMZ-resistant GBM cells ( Kim et al, 2015 ). Moreover, mutations/deregulation in the platelet-derived growth factor receptor alpha ( PDGFRα ), telomerase reverse transcriptase ( TERT ), epidermal growth factor receptor ( EGFR ), c-Myc, phosphatase and tensin homolog ( PTEN ), serine/threonine-protein kinase ( BRAF ) are frequently observed in glioma, which have become attractive markers for targeted therapy [ Mukasa et al, 2010 ; Sampson et al, 2010; Killela et al, 2013 ; Johnson et al, 2014 ; Liu et al, 2020a ; Liu et al, 2020b )].…”

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer

“…However, even in the same cancer type, substantial variability has been observed indifferent patients (4,8,9). Mutational analysis of ctDNA has already been proven to be promising in early cancer detection and cancer recurrence evaluation (10)(11)(12)(13)(14)(15).…”